Skip to main content

Advertisement

Table 3 Plasma concentrations of darunavir and elvitegravir at 24 h post-dose

From: HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study

Study intervention N Darunavir Ctrough,ss, ng/mL Elvitegravir Ctrough,ss, ng/mL Refs.
Median/mean Range Median/mean Range
DRV/rtv, pre-switch 5 981 (median)
932 (mean)
667–1150
 
E/C/F/TDF + DRV 9 482 (median)
490 (mean)
96–848 184 (median)
200 (mean)
<  80–435  
DRV/rtv 800/100 mg 335a 2041 (median) 368–7242 [22]
119 1820 (mean) IQR 1470–2460 [23]
DRV/cobi 800/150 mg 298a 2150 (mean) SD 1320 [25]
59 1311 (mean) SD 969 [25]
32 1319 (mean) 288–3641 [24]
E/C/F/TDF (no DRV) 419a 451 (mean) 58–2341 [26]
32 250 (mean) 30–762 [24]
E/C/F/TDF + DRV 24 1294 (mean) 163–3641 234 (mean) 92–432 [24]
8 273 (median)b 164–501 (IQR)b [12]
E/C/F/TAF + DRV 15 1250 (mean) NA 464 (mean) NA [36]
  1. C trough,ss trough plasma concentration at steady-state, DRV darunavir, rtv ritonavir, cobi cobicistat, E/C/F/TDF elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate, E/C/F/TAF elvitegravir/cobicistat/ emtricitabine/ tenofovir alafenamide, IQR interquartile range, SD standard deviation, NA not available
  2. aPopulation pharmacokinetic estimate; b estimated